Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Beijing Infervision Completes D1 Funding for AI-based Image Reading Products

publication date: Dec 3, 2020

Infervision, a Beijing company that develops AI-based imaging readers, completed a D1 financing round of undisclosed size. Founded in 2014, Infervision has launched eight programs that are fully integrated with medical workflows to aid the reading of scans. Its products are available in more than 10 countries in Asia, Europe and North America. The D1 round was led by Zhongguancun M&A Fund of Funds, with participation from Zhongguancun Science City, Shenzhen Yicun Tongsheng, Shanghai Lianyi and previous shareholders. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital